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Geographical variation in Plasmodium vivax relapse
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Abstract
Background: Plasmodium vivax has the widest geographic distribution of the human malaria parasites and nearly
2.5 billion people live at risk of infection. The control of P. vivax in individuals and populations is complicated by its
ability to relapse weeks to months after initial infection. Strains of P. vivax from different geographical areas are
thought to exhibit varied relapse timings. In tropical regions strains relapse quickly (three to six weeks), whereas
those in temperate regions do so more slowly (six to twelve months), but no comprehensive assessment of
evidence has been conducted. Here observed patterns of relapse periodicity are used to generate predictions of
relapse incidence within geographic regions representative of varying parasite transmission.
Methods: A global review of reports of P. vivax relapse in patients not treated with a radical cure was conducted.
Records of time to first P. vivax relapse were positioned by geographic origin relative to expert opinion regions of
relapse behaviour and epidemiological zones. Mixed-effects meta-analysis was conducted to determine which
geographic classification best described the data, such that a description of the pattern of relapse periodicity within
each region could be described. Model outputs of incidence and mean time to relapse were mapped to illustrate
the global variation in relapse.
Results: Differences in relapse periodicity were best described by a historical geographic classification system used
to describe malaria transmission zones based on areas sharing zoological and ecological features. Maps of incidence
and time to relapse showed high relapse frequency to be predominant in tropical regions and prolonged relapse in
temperate areas.
Conclusions: The results indicate that relapse periodicity varies systematically by geographic region and are categorized
by nine global regions characterized by similar malaria transmission dynamics. This indicates that relapse may be an
adaptation evolved to exploit seasonal changes in vector survival and therefore optimize transmission. Geographic
patterns in P. vivax relapse are important to clinicians treating individual infections, epidemiologists trying to infer
P. vivax burden, and public health officials trying to control and eliminate the disease in human populations.
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Background
Malaria is a significant global public health problem and
the greatest burden of disease is found in the world’s
poorest countries [1]. The majority of malaria morbidity
and mortality is caused by two of the five species of
Plasmodium that naturally infect humans, Plasmodium
falciparum and Plasmodium vivax. The broader global
distribution of P. vivax relative to P. falciparum puts an
estimated 2.5 billion people at risk for endemic vivax
malaria [2,3]. An increasing body of evidence has shown
that P. vivax should no longer be thought of as a benign
and rarely fatal disease [4-9], but instead as being cap-
able of causing severe disease and death, particularly in
pregnant women and small children [9-12].
Plasmodium vivax is epidemiologically and biologically
different to P. falciparum and it is not, therefore, appro-
priate to assume that control methods developed for
falciparum malaria are directly transferable to P. vivax
[13-16]. Biological features of P. vivax that distinguish it
from P. falciparum also present unique challenges to
the control of the parasite [17-19]; in elimination set-
tings, P. vivax is often the “last parasite standing” following
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P. falciparum elimination [20,21]. Plasmodium vivax ga-
metocytes are present earlier in the progression of a pri-
mary or recrudescent infection compared to P. falciparum
[17,22], such that the majority of patients have sufficient
gametocytaemia to allow for transmission before diagnosis
or treatment may occur [23-25]. In addition, P. vivax ga-
metocytes are transmitted more efficiently to Anopheles
mosquito vectors than those of P. falciparum and are
transmissible at lower parasite densities [18,26,27]. Within
the mosquito, P. vivax sporozoites develop faster than P.
falciparum at equivalent temperatures, which contributes
to its exploitation of a wider geographic range [28].
Perhaps the most epidemiologically important feature
of P. vivax biology is its ability to relapse in the weeks
and months following a primary parasitaemia via a dor-
mant liver stage known as the hypnozoite [29-31]. This
potential for long-term latency provides the obvious ad-
vantage of safe harbour during cold winter months when
circulation in blood creates potential host immune sys-
tem dangers without the benefit or opportunity for on-
ward transmission. Therefore the term “infection” has
various meanings for P. vivax. Infection may refer to the
introduction and presence of parasites in the body, but
with P. vivax, unlike P. falciparum, this can also refer to
a symptom-less latent infection. The origin of renewed
parasitaemia following a primary vivax infection or a
“recurrence” is also ambiguous; it could be due to a
hypnozoite-triggered relapse, a resurgence of erythro-
cytic parasites as a recrudescence, or an entirely new re-
infection. See Figure 1 and Table 1 for a description of
the pathways between types of infection and attack, and
distinctions in terminology. The hypnozoite fundamen-
tally distinguishes P. vivax from P. falciparum in almost
every important biological, epidemiological, clinical, and
public health respect.
The hypnozoite stage in the life cycle of P. vivax and
the potential for relapse makes chemical therapies that
target only the blood stage of infection ineffective as a
radical cure. The 8-aminoquinolines are the only class of
drugs known to have activity on the hypnozoite parasite
[32-34]. Primaquine therapy, the only currently licensed
radical cure, comes with caveats that add to the chal-
lenge of controlling the parasite to the point of elimin-
ation. Primaquine is associated with potentially fatal
haemolysis in individuals with glucose-6-phosphate de-
hydrogenase (G6PD) deficiency [32,35,36] and is contra-
indicated in pregnant women because of the risk of
acute haemolytic anaemia in the foetus of unknown
G6PD status [37]. The hypnozoite stage and the paucity
of therapy for safe and effective treatment render vivax
malaria an exceedingly difficult challenge for clinicians
and those responsible for the control of endemic mal-
aria. Relapse also has critical implications for under-
standing epidemiological metrics such as the basic
reproduction number and force of infection, obtained
from prevalence rates derived from malariometric sur-
veys and cartographic studies that form a central part in
elimination scenario planning [38,39].
It has long been known that there is significant
geographical variation in the rate at which a “strain” of
P. vivax relapses [40-42]. Temperate and subtropical
strains often exhibit either a long incubation or latent
period (Figure 1) of around eight to ten months. Trop-
ical strains are characterized by short incubation times
and short latency (approximately three to six weeks) [43].
Incubation period refers to the time from sporozoite
Figure 1 Pathways to infection of blood and clinical attacks in Plasmodium vivax malaria.
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inoculation (the mosquito bite) to the primary blood-stage
infection. The latent period describes the time from the
primary attack to relapse. How hypnozoite relapse is trig-
gered, and the source of this phenotypic variation, is unre-
solved [44]. One theory is that the mechanism is an
adaptive trait of the parasite to sequester or “hibernate”
during times when climatic conditions would be inhospit-
able to the parasite’s anopheline mosquito vectors [45-47].
Another is that latent hypnozoites are activated by a sys-
temic febrile illness, explaining the large number of P.
vivax relapses that follow P. falciparum infections [47-49].
These hypotheses need not be mutually exclusive.
Regardless of the triggering mechanism and aetiology
of relapse, evidence from both controlled experimental
and natural settings indicate considerable geographical
variation in the timing of relapse. Although the historical
perception has been that frequent relapsing strains ori-
ginate from the tropics and long-latency strains from
temperate regions [31], it does not sufficiently describe
the observed variation in relapsing phenotypes. This bin-
ary classification conflicts with evidence of long-latency
strains in tropical regions in the Americas, for instance.
Coatney et al. [43] described in 1971 that there were
three patterns of relapse. These included the Chesson
strain of New Guinea-South Pacific which exhibits a
short incubation period (seven to fourteen days), fol-
lowed by regular re-invasions of the bloodstream within
approximately three weeks after the primary infection
and may continue to relapse for more than 18 months
without a radical cure of the hypnozoite stage. The St
Elizabeth strain from southern USA has a similar incu-
bation period to the Chesson strain, but hypnozoites re-
main quiescent for several months following the primary
infection before relapsing at regular intervals of three to
four weeks for up to two years [43]. A third variety, such
as the strain once found in the Netherlands [42], has a
long period of incubation (around eight months) before
the primary clinical episode followed by frequent re-
lapses (the lower arm of Figure 1). This three-type classi-
fication likely oversimplifies the degree of variation in P.
vivax relapse periodicity and offers limited information
regarding the geographic origin of the described pheno-
types. Furthermore, the majority of P. vivax strains have
short incubation periods and the greatest difference lies
in the latency period from primary attack to first relapse.
Geographic zones have been proposed for distinguish-
ing areas with similar timing and frequency of P. vivax
relapse following sporozoite inoculation. Figure 2A,
adapted from White [47], and modified by the boundar-
ies of the malaria endemicity map proposed by Lysenko
and Semashko (for the maximum range of malaria circa
1900) [50], illustrates a proposed distribution of relapse
phenotypes. White noted the historical perception that
strains that relapse quickly originate from Southeast
Asia. Temperate and subtropical areas are characterized
by long-latency strains. The Indian subcontinent and
South America are thought to contain both long-latency
and frequent relapsing strains. A second geographic de-
scription of variation in time to relapse is described in a
recent study by Lover and Coker [51]. The authors ana-
lysed the time to relapse in experimentally infected indi-
viduals relative to the geographic origin of the strain.
They found that, overall, temperate strains relapse more
slowly than tropical ones. However, they also found that
New World tropical strains relapse more slowly than
Old World tropical strains, and Eurasian temperate
strains relapse more slowly than temperate strains from
the Western Hemisphere [51]. Figure 2B illustrates this
implied classification system.
While the maps in Figure 2 were derived from obser-
vations of relapse phenotype, others have grouped re-
gions based on similar ecological and epidemiological
Table 1 Glossary of terms relevant to Plasmodium vivax relapse
Term Definition
Infection Presence of parasites in any of its forms of incubation, prepatency, patency, subpatency or latency.
Incubation The period between inoculation of sporozoites and release of merozoites into the blood stream (primary exo-erythrocytic cycle).
Prepatency The period prior to a primary attack where asexual parasites in the blood are both not detectable and asymptomatic, though present.
Patency The period of clinical attack with demonstration of asexual parasites in blood as the cause of illness.
Subpatency The period following a primary attack where asexual parasites are both not detectable and asymptomatic, though present.
Recrudescence An event following sub-patency when parasites are both demonstrated to be present and the cause of another clinical attack
or asymptomatic patency.
Latency The period between a primary attack and a relapse; in some strains also the period between inoculation of sporozoites and the
occurrence of a patent primary attack, typically six months or more.
Relapse Patent asexual parasitaemia originating from activation of latent hypnozoites.
Re-infection Patency by asexual blood stage parasites deriving from a new inoculation of sporozoites.
Recurrence A newly patent parasitaemia occurring at any point after clearance of sub-patency of a primary parasitaemia where the origin is
not known with certainty as being a reinfection, recrudescence or relapse.
Definitions are presented in chronological order of events.
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characteristics in the absence of relapse observations.
These regions may reveal patterns of relapse and help
elucidate determinants of the periodicity observed. The
zones proposed by Macdonald [52] are shown in
Figure 3. They are described by Macdonald as “zoogeo-
graphical” malaria regions and share commonalities with
many historical biogeographical zonations [53-55]. The
approximate boundaries of the zones are delineated by
climatic variables that influence malaria transmission
rates, such as temperature and rainfall, the intensity of
transmission observed, as well as the abundance and be-
haviours of the locally dominant vector species [52].
A systematic review of P. vivax relapse events was
conducted with the aim of revealing systematic geo-
graphical patterns of relapse frequency and a quantita-
tive description of the potential time to relapse in
different regions of the P. vivax-endemic world.
Methods
Data assembly
A formal literature search for data was conducted on
PubMed [56] with the keywords: “vivax AND relapse”
on 15 November, 2012 and updated on 24 October,
2013. The search returned 449 references. This list was
Figure 2 Proposed distributions of Plasmodium vivax relapse latency phenotypes. Panel A, adapted from White [47], shows the historical
distribution of frequent relapsing and long-latency relapse strains. The geographic limits were modified using a historical malaria endemicity map
from Lysenko and Shemashko [50]. Tropical frequent relapsing strains are in pink and long-latency strains in grey. Much of Africa is shown with
grey hatching because the influence of Duffy negativity and its effect on vivax transmission in this part of the world is not yet understood. Purple
areas are thought to have both long-latency and frequent relapsing strains. Panel B shows the Old and New World classification system based on
the analysis and findings from Lover and Coker [51]. Tropical zones (red and pink) harbour strains that relapse more quickly than those in temperate
zones (light and dark blue). New World tropical strains (pink) relapse more slowly than Old World tropical strains (red) and Old World temperate strains
(dark blue) relapse slower than New World temperate strains (light blue). The dotted lines indicate the ±23.5° latitude lines to delineate temperate and
tropical areas. Old World refers to Africa, Eurasia and the Pacific and New World to the Americas and Caribbean regions.
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augmented with the reports of P. vivax relapse cited by
Baird and Hoffman [32] and from the reference list of
two recent reviews of variation in relapse periodicity
[47,51]. Additional studies were obtained by correspond-
ence with colleagues active in this research area. Malaria
in the military was also examined using references from
the US Army and medical records from British soldiers
who contracted malaria during duty in World War II.
Medical records were obtained from contacts and the
Malaria Research Library, now the Malaria Reference
Library, kept at the London School of Hygiene and
Tropical Medicine. The aim was to obtain as much data
as possible regarding P. vivax recurrence in all regions
where vivax malaria is or has been endemic. The litera-
ture sources ostensibly refer to the recurrence events as
relapses; however treatment trials and studies conducted
in endemic areas may include recrudescences and rein-
fections in measures of relapse. Because much of the
data on P. vivax relapse in patients not treated with
primaquine originated before use of the drug became
common following World War II [57], no restrictions
were applied on study dates.
The exclusion criteria for the studies were minimal.
Data were not used from patients who had been treated
with a sufficient dose (15 mg per kg for 7 or 14 days) of
primaquine, or any 8-aminoquinoline drug (pamaquine,
plasmochin or pentaquine), due to the effect of the drug
on hypnozoites, and therefore patterns of relapse. For
example, a series of clinical trials demonstrated that 8-
aminoquinoline drug failures (relapses) occurred 60–
90 days post-patency, whereas untreated relapses almost
always occurred between day 17 and day 35 post-
patency [58]. Studies that had treated patients with a
five-day course of 15 mg base of primaquine or less,
which was shown to be ineffective in preventing relapse
[59], were permitted. Relapse in patients treated with a
seven-day course of primaquine in South America,
where the treatment schedule has been shown to be in-
adequate [60], were also considered. Blood-stage treat-
ments were not exclusion criteria, but were noted for
analysis purposes. Mefloquine prophylaxis and treatments
such as mepacrine (quinacrine, atabrine) or chloroquine
may cause a delay in relapse because the drugs retain
suppressive levels in the patient for long periods after
treatment [61,62], making it difficult to distinguish the ob-
served relapse as a first or second relapse. A 14-day cut-
off was applied to data abstracted from drug treatment
trials. Any re-appearance of infection before the 14th day
was categorized as a treatment failure, while infection after
day 14 was listed as a relapse. This conservative cut-off
was applied to maximize sensitivity. A primary relapse is
unlikely to occur before two weeks, even in fast relapsing
strains [63]. However, a 14-day cut-off may result in some
recrudescence events being classed as a relapse.
When possible, data on time to recurrence from the
start of treatment of the primary infection were ab-
stracted to the individual level. Start of treatment was
almost invariably the first day of patency, and we consid-
ered it most probable that the vast majority of recur-
rences represented relapses. The majority of studies
reported by the day, but those that reported the week or
month of relapse were also included (with the last day of
the month or week given as the time to relapse). Studies
that aggregated months together were excluded. The
period of follow-up was recorded for all individuals in
each study, including those that did not experience a re-
lapse. Data on the type of patient (prison volunteer, mal-
aria therapy patients, soldiers, etc.) were also collected
Figure 3 Zoogeographical zones of malaria transmission. Zones defined by Macdonald (1957) based on regions with similar ecological and
epidemiological characteristics [52].
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as it is likely that this would have influenced the time to
first relapse. Data on duration of prepatent period from
studies performed in experimental settings were re-
corded where this information was available.
Georeferencing
Geopositioning of relapse studies was implemented using
established methods [64] for those references that did not
provide specific coordinates for the study site. The latitude
and longitude of entries that provided cities or towns were
located as points (<10 sq km) using Google Maps [65].
The centroid of small and large polygons (>25 to <100 sq
km and >100 sq km, respectively), such as islands, regions
or countries were obtained using ArcMAP 10.0 [66] to de-
termine the latitude and longitude of those areas. The lati-
tude and longitude values recorded corresponded to the
origin of infection. Therefore, infections in returning trav-
ellers were geopositioned to the place of travel and malaria
therapy or experimental trials were positioned to the ori-
gin of the strain used.
Statistical analysis
The number of cases, total person time observed, and
mean and standard deviation of time to first relapse were
calculated among individuals who experienced at least one
relapse in each study. The incidence rate of relapse was
calculated from the number of relapse events and total
person time. The factors affecting this rate were modelled
using mixed-effects meta-analysis in the package metafor
[67,68] within the statistical programming language R
[69]. As data must be normalized for use in metafor, how
to best accomplish this was tested by applying different
transformations to the data from each study and assessing
deviation from normality by the Shapiro-Wilk test.
The geographic zones described above (Figures 2 and 3)
were included in the meta-analysis of relapse rate as cat-
egorical moderators. These included the three phenotypic
zones shown in White (hereafter referred to as the White-
3 system), which were also shown differentiated by Old
World and New World (White-5), the four zones de-
scribed by Lover and Coker, and lastly the 12 zoogeo-
graphical regions as described by Macdonald [47,51,52].
Model choice was performed between these geographic
systems using information criteria given by metafor (see
Table 2). For the best geographic system obtained from
this, a meta-analysis of mean time to first relapse among
patients with observed relapse events was performed. See
Additional file 1 for more information regarding model
choice and the meta-analysis. Kaplan-Meier survival
curves were generated from pooled individual data from
each zone. These curves are intended to illustrate the ob-
served qualitative patterns of relapse in each zone.
Relapse maps
To visualize geographic variation in relapse, maps were
generated by plotting points of median time to relapse
in individuals who experienced a relapse from each
study included in the final dataset. Regional maps were
produced to illustrate the relapse incidence and mean
time to relapse modelled within the geographic system
chosen in the meta-analysis.
Results
Data assembly
Following the literature search and collection of unpub-
lished sources, 121 references were found to contain data
on time to first recurrence in patients not treated with a
sufficient radical cure. Further details regarding the results
of the literature review are found in Additional file 1. De-
tails and summary statistics for the 121 references show-
ing time to first recurrence are shown in Additional file 2.
Of those, 87 references reported data at the individual
level with time to relapse reported in days or values less
than or equal to one month (Figure 4). The resulting data-
set contained information on 30,049 individuals, of whom
5,731 experienced at least one recurrence. These data are
provided in Additional file 3. The observed recurrences
are most likely to be relapses, but, in probably rare in-
stances, recrudescences may also be represented among
data classified as early relapse (<60 days). The list of ref-
erences included in the final database is available in
Additional file 4.
Relapse rate data were available from 29 different
countries and regions. The vast majority of the data were
from India (78%, 23537/30049); although of the patients
to experience a relapse, only one third (34%, 1931/5731)
originated from the subcontinent (Additional file 1).
There were data from 23 known strains in experimental
infections, but the majority of individuals contracted
wild P. vivax (94%, 28149/30049). Many of the subjects
were not residents of endemic areas. For example, over
one third of the patients to relapse (37%, 2731/5731) were
Table 2 Comparison of geographic classification systems
System τ2 I2 H2 R2 AIC AICc
White-3 1.3 97.1 34.0 33.6% 707.7 707.9
Lover 1.6 97.5 40.8 19.4% 728.4 729.0
White-5 0.9 95.4 21.8 57.3% 623.6 624.0
Macdonald 0.8 95.0 20.0 59.9% 612.7 614.1
Modified Macdonald 0.8 95.0 19.9 60.1% 612.9 614.0
Mixed-effects meta-analysis has been performed for 214 different studies or
study arms by using the R package metafor [68]. The statistics are: τ2, amount
of residual heterogeneity; I2, residual heterogeneity/unaccounted variability;
H2, unaccounted variability/sampling variability; R2, calculated from the residual
heterogeneity (τ2) and the residual heterogeneity of an empty model as
suggested by Raudenbush [70]; AIC, Akaike information criterion; and AICc,
corrected AIC. The values of AIC, BIC and AICc are based on the restricted
maximum likelihood, as this corresponds to the REML (restricted maximum
likelihood) estimator recommended by experts [67].
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military personnel deployed from non-endemic regions. A
summary of key aspects of the dataset, such as treatment
and patient type, is available in Additional file 1.
Statistical analysis
Regardless of the transformation applied to the raw data
for each study (identity, log, square root or Freeman-
Tukey [71]), the time to first relapse deviated significantly
from normal (plots shown in Additional file 1). The devi-
ation was smallest under the log-transformation, which is
common for incidence-rate data [72]. The model choice
analysis was therefore carried out using log-transformed
data. The Macdonald classification system yielded the best
description of the data, judging by pseudo-R2, the Akaike
information criterion (AIC) and corrected AIC (AICc,
which accounts for small sample sizes, see Table 2). Pos-
sible ways to simplify the Macdonald system such that
geographically contiguous zones with similar transmission
suitability would be combined were assessed. Further de-
tails are provided in Additional file 1. Combining zones 4
and 11 slightly improved the model fit. Zones 5 and 6, and
9 and 10, respectively, were also combined as there were
no relapse data available from zones 6 and 9. The revised
zones are shown in Figure 5A.
Table 3 presents two estimates of relapse incidence
rate for the modified Macdonald system as the number
of first relapses per 100,000 person days. One is the
crude estimate based on raw data, and the other is the
Figure 4 Schematic overview of the literature review procedure and results to obtain individual records of relapse and follow-up.
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Figure 5 (See legend on next page.)
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result obtained from the meta-analysis. The highest ob-
served and predicted incidence values are found in zones
9 + 10 and 12, corresponding to Southeast Asia and
Papua New Guinea (PNG) plus the Solomon Islands
(Melanesia). It is predicted that there will be approxi-
mately 800–1,200 relapses per 100,000 person days in
this part of the world, compared with the estimated 130
relapses in northern Asia and Europe (zones 4 and 11).
The crude and predicted estimates are very different for
some zones (namely 3 and 8). This is because the
mixed-effect meta-analysis attributes unusually low and
high case numbers to inter-study variation and these do
not contribute substantively to the rate estimate. A rele-
vant incidence measure could not be calculated for zone
8 (India) because the observed data included several
large studies (>2,000 patients) in which the majority of
patients did not experience a relapse (Additional file 1).
Table 4 shows the raw and modelled estimates of mean
relapse time for each of the geographic zones in the modi-
fied Macdonald system. These were obtained by running a
meta-analysis for mean time to relapse and its standard
deviation within each study (in a separate analysis from
the original run for the incidence rates), and these are cal-
culated from only the observed relapse events. This pro-
duces a modelled estimate of relapse time that is based on
the least variable data sources. The Indian zone figures are
therefore more plausible in these results. The modelled
results show the fastest times to relapse are found in
Southeast Asia (zone 9 + 10) and Melanesia (zone 12),
around 45 days. South America (zone 3) also had a rapid
time to relapse (65 days). However, there were relatively
few records from zone 3 (Figure 5B) and some of the het-
erogeneity in relapse patterns may have been missed. Zone
1, North America, is predicted to have relapse times of
about six months. Central America, zone 2, is estimated to
have a relapse time of five to six months, driven by a few
studies with long relapse intervals observed in Mexico [74].
The Mediterranean zone (5 + 6), a region of seasonal trans-
mission, has a modelled mean time to relapse of five
months. Based on the raw data, the mean time to relapse
from the few data points in the sub-Saharan Africa zone (7)
was only one month. Finally, the northern Europe and Asia
zone (11 + 4) has by far the longest modelled mean time to
relapse of ten months.
Finally, Figure 6 presents the survival curves for the
modified Macdonald system. Note that the meta-analysis
models described above do not yield survival curves. The
curves in Figure 6 are based on the Kaplan-Meier survival
function estimator, and they are calculated from pooled
raw data within the geographic zones to provide a quantita-
tive comparison of relapse patterns among zones. For
(See figure on previous page.)
Figure 5 Revised zoogeographical zones and observed time to first relapse. Panel A illustrates the revised zoogeographical zones used to
describe the time to first relapse. Panel B shows the median observed time to relapse in each study used to obtain individual data. The size of
each point varies by sample size and the time to first relapse is shown on a spectrum of red (less than one month) to dark blue (>12 months).
Violin plots in Panel C show the observed time to first relapse in individuals from each zone in Panels A and B. The coloured areas correspond to
each zone and to a smoothed approximation of the frequency distribution (a kernel density plot) of the time relapse within each geographic
region. The black central bar represents the interquartile range and the white circles indicate the median values. Note that the maximum value
for zone 2 extends beyond the plot.
Table 3 Relapse incidence rates for the modified Macdonald
system
Ecological zone Based on raw data,
ML with 95% CI
Model-based,
REML with 95% CI
1 357 (CI: 318–400) 455 (CI: 313–662)
2 217 (CI: 198–238) 259 (CI: 120–557)
3 419 (CI: 328–528) 1093 (CI: 535–2,233)
5 + 6 214 (CI: 186–245) 262 (CI: 82–839)
7 221 (CI: 191–255) 213 (CI: 95–477)
8 25 (CI: 24–26) 62 (CI: 33–116)
9 + 10 975 (CI: 811–1163) 836 (CI: 351–1,995)
11 + 4 138 (CI: 120–159) 134 (CI: 64–278)
12 1023 (CI: 981–1,067) 1224 (CI: 689–2,174)
The numbers are presented as first relapses per 100,000 person days. The
estimate based on raw data is obtained by dividing the number of relapses by
follow-up time and using Ulm’s exact formula [73] for confidence intervals. The
model-based estimates are calculated from the results obtained from meta-
analysis performed by the R package metafor. ML refers to the maximum
likelihood and REML to restricted maximum likelihood.
Table 4 Mean time to relapse among geographic zones
Ecological zone Based on raw data,
ML with 95% CI
Model-based,
REML with 95% CI
1 100 (CI: 99–101) 185 (CI: 162–208)
2 239 (CI: 239–240) 164 (CI: 117–212)
3 53 (CI: 53–53) 65 (CI: 18–113)
5 + 6 153 (CI: 153–153) 151 (CI: 80–221)
7 31 (CI: 30–31) 107 (CI: 57–158)
8 181 (CI: 180–181) 120 (CI: 82–159)
9 + 10 289 (CI: 288–290) 41 (CI: −11–92)
11 + 4 89 (CI: 87–90) 299 (CI: 254–345)
12 122 (CI: 121–123) 47 (CI: 12–81)
The model-based estimates have been calculated by using the R package
metafor, which acknowledges interstudy variation. Thus the numbers differ
from raw means calculated from the data. ML refers to the maximum likelihood
and REML to restricted maximum likelihood. Please note that sample means by
the very definition concern only observed events, and consequently this table
ignores person time from censored observations.
Battle et al. Malaria Journal 2014, 13:144 Page 9 of 16
http://www.malariajournal.com/content/13/1/144
example, in zone 1, the majority of the patients observed
had relapsed by day 300, whereas in zone 12, most patients
had relapsed before day 100. The curve in zone 8 does not
reveal much regarding the time to relapse because of the
small number of relapsing patients.
Relapse maps
The revised zoogeographical zones used in the analyses
described above are shown in Figure 5A. In Figure 5B
the median time to relapse for study locations is speci-
fied with points inside the geographic zones. The map il-
lustrates a concentration of fast-relapsing strains in
Southeast Asia and Melanesia. The heterogeneity in re-
lapse periodicity observed in zone 8 is also apparent in
this map. The variation in the North American zone is
due to the behaviour of strains occasionally relapsing
quickly after a long incubation period between inoculation
and primary attack (data available from experimental
Figure 6 Survival curves for the modified Macdonald system. Shown are the Kaplan-Meier estimates (solid lines) with 95% confidence intervals
(dotted lines). For each curve, all individual-level data from the respective zone have been pooled. The curves terminate at the longest follow-up day
in each zone. The ticks indicate censoring events, i.e., losses to follow-up or the completion of a study without relapse. Zone 1: North America, zone 2:
Central America, zone 3: South America, zone 5: Mediterranean and North Africa, zone 7: sub-Saharan Africa, zone 8: Monsoon Asia, zone 10: Southeast
Asia, zone 11: northern Europe and Asia, zone 12: Melanesia.
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inoculations only), but for the most part relapses followed
a long period of latency after a short incubation period.
Summary statistics of the time to relapse by zone are
shown in Additional file 1. Panel C in Figure 5 is a violin
plot of observed time to relapse in each zone. This illus-
trates that those shorter relapses in North America are
fairly rare. The violin plots also show that the longer pe-
riods to relapse in Central America and Southeast Asia
are rare. Heterogeneity in other zones, such as 8 and 11 +
4, is also demonstrated by the violin plots. Figure 7 illus-
trates the results of the predicted relapse incidence and
mean time to relapse by region. In Figure 7A, zone 8 is
hatched out as the resulting estimate is biologically im-
plausible and is most likely caused by the handful of stud-
ies with large numbers of patients not reporting relapse
during the observation period.
Discussion
The aims of this paper were to review the timing and
frequency of P. vivax relapse of known origin in patients
not treated with a hypnozoitocide to characterize vari-
ance in these patterns within geographic dimension, to
identify a system to classify the variation in relapse ob-
served and to describe the pattern of relapse in each
area. A modified classification of the zoogeographical
zones of malaria transmission outlined by Macdonald
[52] was found to best describe the observed variation in
relapse incidence. The rate of relapse and mean time
from primary infection to relapse was predicted in each
of the nine zones. These quantitative estimates of the
contribution of relapses to P. vivax case incidence are
crucial in informing estimates of disease burden and the
origin of acute attack, i.e., from biting mosquitoes or
Figure 7 Modelled relapse incidence and mean time to relapse. Panel A illustrates the relapse incidence per 100,000 person days on a
spectrum of blue to red, with red being the highest incidence of relapse. Zone 8 is hatched to indicate that the predication is particularly
uncertain. Panel B illustrates the predicted mean time to relapse on a spectrum from blue to red, with red being most frequent relapse. The
numbers of the zones correspond to those shown in Figure 5A.
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emergent hypnozoites. This understanding, in turn, in-
forms critical decision-making in control strategies that
effectively weigh the benefit of anti-mosquito versus hyp-
nozoitocidal interventions. They also help identify re-
gions in which strains have long-term latency and are
therefore undetectable to standard diagnostic methods
(rapid diagnostic tests and microscopy) for long periods
of time.
The results presented here further refine historical in-
terpretations and recent analyses of the geographic vari-
ation in relapse periodicity. As shown in Figure 2,
tropical strains relapse more rapidly than temperate
strains and New World strains vary from those in the
Old World. White’s illustration of the variation in re-
lapse phenotype shown in Figure 2A shows that South-
east Asia and Asia-Pacific is the only region having
exclusively frequent relapse behaviour. The results also
showed infections from this region to relapse quickly,
with a few rare exceptions. White showed that both fre-
quent relapsing and long-latency strains are present in
India and South America. The data from India appear to
affirm this, with relapse patterns from the subcontinent
and surrounding areas so heterogeneous that it was im-
possible to generate logical model predictions of relapse
incidence for the region. The low incidence in region 8
shown in Table 3 is not believed to be a reflection of the
presence of long relapsing strains, but rather a result of
natural infections that either did not result in a relapse
or the resulting parasitaemia was too low to be detected
by the study. There is not presently an explanation for
the lack of relapses, but this phenomenon has also been
observed in recent tafenoquine trials in India [75]. The
variation in relapse timing in the raw data observed in
India (Figure 5B) is likely a result of the wide variation
in transmission settings found within this zone. There
are tropical forest areas, similar to zone 12, dry habitats
like those in zone 5 and highland areas that border zone
11. In addition, the presence of Anopheles stephensi,
adapted to breeding in artificial water collections [76,77],
has extended transmission into urban areas. Therefore,
in addition to issues of data availability and study design,
the range of ecological settings in the zone, and likely
some of the other zones, may also contribute to the vari-
ance in relapse behaviours observed.
The results presented for South America were differ-
ent from what was shown in White’s phenotype map
(Figure 2A). South America was predicted to have a high
relapse incidence, comparable to Southeast Asia, and a
two-month mean time from primary attack to relapse.
The data available from this region were limited and de-
termining the cause for the observed difference is there-
fore difficult. There has been renewed interest in the
origin of the American strains of P. vivax, whether they
originate from somewhere in Asia or were sent west from
Africa by migration and the slave trade, as has been pro-
posed for P. falciparum [78]. This could influence the
nature of the relapse periodicity observed. Improved un-
derstanding of the phylogeny of P. vivax may reveal infor-
mation about the pattern of relapse in this region.
The analysis by Lover and Coker [51] revealed that
tropical regions relapse more quickly than temperate
strains. However, Central America and sub-Saharan
Africa had relapse patterns similar to the Mediterranean
with moderate relapse incidence (around 250 relapses
per 100,000 person days) and five to six months between
primary infection and relapse. These regions seem to be
better described as an “intermediate” relapsing pheno-
type between the frequent relapsing strains in Southeast
Asia and South America and the long-latency temperate
strains in North America and Europe/Asia.
The results of the northern temperate regions concur
with the findings of Lover and Coker [51]. The authors
noted that while in general, temperate strains relapse
more slowly than tropical strains and that New World
tropical strains were slower than Old World strains, the
opposite was true of the temperate strains. Based on this
analysis, the New World temperate strains relapsed
more rapidly than the Old World temperate strains
(Figure 7). The modelled results showed that the relapse
incidence was 455 per 100,000 person days and mean time
to relapse was six months in North America. However,
again, this high incidence compared to that in northern
Asia and Europe (134 relapses per 100,000 person days)
could be due to a few exceptional experimental subjects
who received large sporozoite inoculations [79-81].
The utility of the predictions made is limited by the
nature of the data available. There are few contemporary
data on P. vivax infections in patients not treated with a
hypnozoitocide. Therefore, much of the data used were
from drug trials on adult workers, military personnel
and prison “volunteers”, as well as data from when mal-
aria was used to treat neurosyphilis patients. The age
and immunity of the patients would perhaps not be rep-
resentative of relapse as it would occur among residents
of the strain region of origin. This could be important
because the children in many endemic settings likely
carry the greatest burden of relapsing infections [82].
Some experimental challenge subjects were inoculated
with relatively heavy sporozoite dosages, a factor that
greatly influences the time from primary attack to re-
lapse [47] and is likely to differ from relapses following
more modest numbers of sporozoites acquired from wild
anophelines. It is straightforward to attribute an infec-
tion as a relapse or re-infection in experimental settings,
but this could not be distinguished for P. vivax infec-
tions acquired in the wild. Effort was made to obtain
studies where the follow-up period was conducted in a
non-endemic area (for example, in a hospital in a city).
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Of the 5731 records of relapse 88% (n = 5030) were ob-
tained from experimental or non-local populations (such
as military personnel). Lastly, the strains used in therapy
and drug trials in the first half of the twentieth century
were of “known” origin and infections were geopositioned
to those sites. However, it is not certain if the strains used
were of their named origin. For example, the “Madagascar”
strain was obtained from an Indian seaman whose last
port of call was in Madagascar [83] and may conceivably,
therefore, originate from elsewhere.
A principal limitation of this work is the inability to
conclusively identify a recurrent infection as a relapse,
recrudesence or reinfection. This is particularly an issue
given the rising rate of resistance to standard treatments
such as chloroquine [84]. In cases of chloroquine failure,
recurrence can occur one to two months after initial
treatment [63], making differentiation between relapse and
recrudescence a challenge. Chloroquine and chloroquine-
combination therapies were by far the most common
treatment regimens (82%, 24787/30049). Of those patients
to receive chloroquine, 2519 patients experienced a re-
lapse or recurrence, 523 of which occurred before 60 days.
This is equivalent to 9% (523/5731) of the relapse records.
In addition, the effect of resistance on recurrence is likely
abated by the historical nature of the dataset. The first
cases of chloroquine-resistant P. vivax were reported in
1989 [85]. Of the 5731 records of relapse, 2080 occurred
before 60 days and 82% of those (n = 1701) were observed
before 1989. Therefore, increased resistance is unlikely to
have a large effect on the results and instances of recrude-
sence being classed as a relapse would have been rare.
While the relapse signal represented in these data cer-
tainly contains some noise due to reinfection or recrudes-
cence, we considered these other sources of recurrences
improbable relative to relapse. Figures 5C and 6 seem con-
sistent with this assumption because recurrence due to re-
infection or recrudescence would have been far more
stochastic than relapse, obscuring or effacing the patterns
shown by the randomness of timing of those events rela-
tive to primary parasitaemia.
There are aspects of the data that were not incorpo-
rated into the analysis performed here that could be ad-
dressed in future work. First, it was difficult to account
for strains with long incubation periods before primary
infection (information only available for a subset of data
from experimental settings) followed by relatively short
time to relapse. This was occasionally exhibited by the
North American St Elizabeth strain and P. vivax multi-
nucleatum from China (see Additional file 3). The link
between the sporozoite dose and latency, mentioned
above, was shown in the literature to be an important fac-
tor in determining relapse patterns [46,86,87], but was not
incorporated into the analysis as it cannot be known for
wild infections. This may be a possible explanation why
the incidence of relapse in North America was greater
than that predicted for Central America. However, this
was likely not a common problem with the experimental
studies used. The majority of studies aimed to induce pa-
tency and the sporozoite inoculations were large, but not
extreme. There were only a handful of studies included
that used particularly large inoculations in order to study
the effect of dosage on relapse pattern [79-81].
The type of patient varied among studies (prison volun-
teers, military personnel, malaria therapy patients, outpa-
tients in an endemic area, etc.) and the drug type and
dosage varied within and among studies. In some studies,
primary attacks were treated with insufficient doses of 8-
aminoquinolines or drugs that have long half-lives. Mepa-
crine has a half-life of up to a month and can delay
relapses by about 30 days [88,89] and chloroquine, the
most common drug in the dataset, can delay parasite re-
appearance by anywhere from two to six weeks [47]. In-
clusion of the subject-type and treatment as explanatory
variables was tested; however, the results were similar to
the simpler model used (see Additional file 1). Finally, the
analysis only addressed the periodicity between primary
attack and first observed recurrence (relapse). The mod-
elled estimates of incidence do not account for multiple
relapses. Both the frequency and number of relapses will
vary based on a variety of factors including inoculums, age
Table 5 Strategies for modelling survival data obtained from many dissimilar sources
Statistical method Accounts for individual-level variation Accounts for
between-study
variation
R packages
Fixed-effects meta-analysis No; operates on summary statistics No Many software packages, e.g., meta and metafor
Mixed-effects meta-analysis No; operates on summary statistics Yes Many packages, e.g., meta and metafor;
also general-purpose software such as
lme4 may be used
Survival analysis for
pooled data
Yes No A number of packages, e.g., survival, eha and flexsurv
Survival analysis with
mixed effects
Yes Yes Most notably R/coxme; flexible software seems to
be hard to find
Data were analysed using mixed-effects meta-analysis, which is common for this type of study. All of the methods have strengths and weaknesses.
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of patient and origin of infection. While many studies did
not follow patients long enough to report multiple re-
lapses, further work in this area will be essential to obtain
measures of the P. vivax force of infection.
In addition to the limitations posed by the data and
survey study designs, the analysis is limited by the types
of statistical methods available for this kind of task (see
Table 5). It would be preferable to use a statistical model
that is both hierarchical (to account for between-study
variation) and employs a suitable survival-analysis likeli-
hood. Unfortunately, software used to fit this type of
model was numerically unstable and hence the mixed-
effects meta-analysis was employed.
The mechanism of hypnozoite activation to cause an
acute attack (relapse) remains unknown. There is clearly
variation in relapse “phenotype”. Based on the results
presented here, timing of relapse appears to vary geo-
graphically in conjunction with areas of similar ecology
and malaria transmission patterns. However, it is difficult
to determine whether long latency occurs in regions of
frequent relapse (tropical areas such as zones 9 + 10 and
12). A long-latency relapse may be thought to be another
short-term relapse in a succession of rapid relapses, and
the genotype cannot reveal if it is in fact a separate relapse
“event” [47]. Nonetheless, understanding broad patterns
of relapse is of use epidemiologically. There tends to be
fewer overall relapses in the long-latency strains because
hepatocytes that host the hypnozoites may die before the
relapse event occurs. The resulting burden of hypnozoites
from different strains or regions has implications for sen-
sitivity to primaquine and therefore the dosage of prima-
quine that should be used [47]. This was observed in
treatment of soldiers returning from Korea (fewer hypno-
zoites) [90] relative to those returning from the Pacific
(high hypnozoite burden) [58] and will have implications
for future control strategies.
Conclusions
Frequency of relapse varies geographically. The associ-
ation between relapse rate and the geographic regions
does not clarify causation. Geographic variation does not
directly imply environmental cues as triggers for relapse,
even if the revised Macdonald system resembles the distri-
bution of transmission suitability. Relapse frequency may
result from evolved responses to average transmission
season duration or arise from proximate cues, such as
triggers from other infections, correlated with P. vivax
transmission and/or vector suitability periods. There is
likely an interaction between activation of latent hypno-
zoites from infection and an evolved trait for strains from
areas of seasonal transmission to remain dormant during
periods of low mosquito abundance. Regardless of the
cause, these patterns are important for the treatment of
individual infections, measures of P. vivax burden and the
prospects for control and eventual elimination of the dis-
ease from endemic areas.
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